trastuzumab emtansine + docetaxel

Trastuzumab emtansine + docetaxel is a **combination therapy** consisting of the antibody-drug conjugate **trastuzumab emtansine** (T-DM1, also known as ado-trastuzumab emtansine) and **docetaxel**, a chemotherapeutic agent. Trastuzumab emtansine is composed of the monoclonal antibody trastuzumab linked via a stable thioether linker to the cytotoxic agent DM1, a microtubule inhibitor. Trastuzumab emtansine specifically targets HER2 (ErbB2)-overexpressing cancer cells, delivering DM1 directly to these cells, resulting in cell-cycle arrest and apoptosis through inhibition of microtubule polymerization. In addition to direct cytotoxicity, trastuzumab mediates inhibition of HER2 signaling and antibody-dependent cell-mediated cytotoxicity. Docetaxel is a microtubule-stabilizing chemotherapeutic agent that also induces mitotic arrest, but through a distinct mechanism. The combination shows enhanced antitumor activity in preclinical and clinical studies, most notably in HER2-positive metastatic and locally advanced breast cancer patients[1][3][4].

Other names

T-DM1 + docetaxelado-trastuzumab emtansine + docetaxel